Logotype for Inventiva S.A.

Inventiva (IVA) investor relations material

Inventiva Investor & Analyst Day summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Inventiva S.A.
Investor & Analyst Day summary8 Oct, 2025

Strategic direction and future plans

  • Transitioning from a development-stage to a commercial-stage company, leveraging new management and leadership to prepare for the 2028 launch of lanifibranor, an oral therapy for MASH.

  • Emphasizing a holistic approach to MASH, integrating liver-directed and cardiometabolic therapies, and anticipating a future with more combination treatments and broader physician involvement.

  • Preparing for a market where most patients may already be on GLP-1 agonists, with lanifibranor positioned as an add-on or alternative for those needing additional liver-directed efficacy.

  • Anticipating increased disease awareness, earlier diagnosis, and a shift toward prevention and integrated metabolic health services by 2028.

  • Organization reinforced with experienced executives and new CEO to support leadership in MASH and commercial launch.

Financial guidance and market outlook

  • Raised over $411 million in PIPE financing, ensuring strong financial positioning to support clinical development and commercialization.

  • The addressable U.S. market for MASH is rapidly expanding, with diagnosed and under-treatment patients up 70% in four years, now at 367,000, and expected to grow further as awareness and screening improve.

  • MASH affects approximately 1.9 million diagnosed patients in the US, with significant unmet need for effective, liver-directed therapies.

  • Real-world practice is shifting toward non-invasive diagnostics and broader use of GLP-1s, with payers and guidelines expected to adapt as new therapies like lanifibranor become available.

  • The company is preparing for reimbursement and adoption challenges, emphasizing the simplicity, tolerability, and broad metabolic benefits of lanifibranor.

Lanifibranor: Mechanism, efficacy, and differentiation

  • Lanifibranor is a once-daily, oral, pan-PPAR agonist designed to address intrahepatic fibrosis and extrahepatic metabolic dysfunction.

  • Demonstrated both MASH resolution and direct fibrosis regression at 24 weeks in Phase 2b, with additional cardiometabolic benefits.

  • Intellectual property protection extends through 2041, supporting durable market exclusivity.

  • Differentiation centers on dual intrahepatic and extrahepatic benefits, oral administration, and potential to address high-risk MASH patients.

  • Favorable safety profile with manageable side effects; most common AEs include diarrhea, nausea, and peripheral edema.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Inventiva earnings date

Logotype for Inventiva S.A.
Q3 2025 TU21 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Inventiva earnings date

Logotype for Inventiva S.A.
Q3 2025 TU21 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of orally administered small molecule therapies for the treatment of serious diseases. The company's research primarily targets conditions related to fibrosis, lysosomal storage disorders, and oncology. Inventiva leverages its proprietary technology platform to identify and develop novel compounds that modulate nuclear receptors, transcription factors, and epigenetic regulation. The company's lead products are developed through strategic collaborations with other pharmaceutical companies, aiming to advance these therapies through clinical trials and regulatory approval. The company is headquartered in Daix, France, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage